- |||||||||| IVAC_M_uID / BioNTech
[VIRTUAL] T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer (eTalks Room) - May 11, 2021 - Abstract #CIMT2021CIMT_8;
P1
In a third arm, patients were vaccinated with IVAC_M_uID, an on-demand manufactured Individualized NeoAntigen Specific Immunotherapy (iNeST) encoding neoepitopes derived from up to 20 cancer mutations determined by next generation sequencing (NGS)...Vaccine-induced CD8+ T cells were of effector/memory, PD1+ phenotype, with a high fraction IFNγ/TNFα/Mip-1a&b triple-positive. This first data suggests that the vaccine is highly efficient in inducing strong poly-epitopic T-cell responses in patients with TNBC in the post-(neo) adjuvant setting, justifying further trials to assess the efficacy of the vaccine in this patient population.
- |||||||||| IVAC_M_uID / BioNTech, BNT114 / BioNTech
Trial completion date: TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov) - Feb 10, 2021
P1, N=42, Active, not recruiting,
This first data suggests that the vaccine is highly efficient in inducing strong poly-epitopic T-cell responses in patients with TNBC in the post-(neo) adjuvant setting, justifying further trials to assess the efficacy of the vaccine in this patient population. Trial completion date: Nov 2020 --> Dec 2023
- |||||||||| IVAC_M_uID / BioNTech, BNT114 / BioNTech
Trial completion date, Trial primary completion date: TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov) - Jan 15, 2020
P1, N=39, Active, not recruiting,
Clinical trial identification: NCT02316457. Trial completion date: Apr 2020 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Jun 2020
- |||||||||| IVAC_M_uID / BioNTech, BNT114 / BioNTech
Enrollment closed: TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov) - Nov 26, 2019
P1, N=39, Active, not recruiting,
Trial completion date: Apr 2020 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Jun 2020 Recruiting --> Active, not recruiting
- |||||||||| IVAC_M_uID / BioNTech, BNT114 / BioNTech
Trial completion date, Trial primary completion date: TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov) - Nov 15, 2018
P1, N=39, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Mar 2019 --> Apr 2020 | Trial primary completion date: Mar 2019 --> Dec 2019
- |||||||||| IVAC_M_uID / BioNTech, BNT114 / BioNTech
Enrollment open, Trial initiation date, Trial primary completion date: TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov) - Oct 12, 2016
P1, N=30, Recruiting,
N=30 --> 42 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Sep 2016 | Trial primary completion date: Dec 2016 --> Mar 2019
- |||||||||| IVAC_M_uID / BioNTech, BNT114 / BioNTech
Trial initiation date: TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov) - Aug 13, 2015
P1, N=30, Not yet recruiting,
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Sep 2016 | Trial primary completion date: Dec 2016 --> Mar 2019 Initiation date: Mar 2015 --> Sep 2015
|
